Daclahep (Daclatasvir Dihydrochloride) is a treatment for chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection. It is prescribed with sofosbuvir, and with or without ribavirin.Dosage and Administration
The recommended dosage in most people is one 60mg tablet taken each day. The tablet is taken orally and should be swallowed whole with a glass of water. It can be taken with or without food.
Treatment with Daclahep (Daclatasvir Dihydrochloride) is usually prescribed for a period of 12 weeks.
Daclahep should always be taken concurrently with Sofosbuvir.
Daclahep should be taken with Sofosbuvir and Ribavarin in the following cases:
- Genotype 1 infection with decompensated cirrhosis
- Genotype 1 infection post-transplant
- Genotype 3 infections with compensated cirrhosis or decompensated cirrhosis
- Genotype 3 infection post-transplant
The most common side effects associated with Daclahep (Daclatasvir Dihydrochloride) and Sofosbuvir treatment are headache, fatigue, nausea and diarrhea.
When Daclahep is taken with Sofosbuvir and Ribavirin people also report anemia, rash, insomnia, dizziness and somnolence as side effects.